These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8557524)

  • 1. Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation.
    Hesse CJ; van Gelder T; Vaessen LM; Knoop CJ; Balk AH; Yzermans JN; Jutte NH; Weimar W
    Immunopharmacology; 1995 Sep; 30(3):237-46. PubMed ID: 8557524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
    Nashan B; Schlitt HJ; Schwinzer R; Ringe B; Kuse E; Tusch G; Wonigeit K; Pichlmayr R
    Transplantation; 1996 Feb; 61(4):546-54. PubMed ID: 8610379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.
    van Gelder T; Baan CC; Balk AH; Knoop CJ; Holweg CT; van der Meer P; Mochtar B; Zondervan PE; Niesters HG; Weimar W
    Transplantation; 1998 Feb; 65(3):405-10. PubMed ID: 9484761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation.
    van Gelder T; Balk AH; Jonkman FA; Zietse R; Zondervan P; Hesse CJ; Vaessen LM; Mochtar B; Weimar W
    Transplantation; 1996 Jul; 62(1):51-5. PubMed ID: 8693545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation.
    van Gelder T; Zietse R; Mulder AH; Yzermans JN; Hesse CJ; Vaessen LM; Weimar W
    Transplantation; 1995 Aug; 60(3):248-52. PubMed ID: 7645037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation.
    Baan CC; Knoop CJ; van Gelder T; Holweg CT; Niesters HG; Smeets TJ; van der Ham F; Zondervan PE; Maat LP; Balk AH; Weimar W
    Transplantation; 1999 Mar; 67(6):870-6. PubMed ID: 10199736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
    Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.
    Wabbijn M; Balk AH; van Domburg RT; Vantrimpont PJ; van Riemsdijk IC; Baan CC; Weimar W; van Gelder T
    Exp Clin Transplant; 2004 Jun; 2(1):201-7. PubMed ID: 15859929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.
    van Gelder T; Knoop CJ; Hesse CJ; Vaessen LM; Balk AH; Yzermans JN; Weimar W
    Transplant Proc; 1995 Feb; 27(1):856-8. PubMed ID: 7879206
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo effects of BT 563, an anti-interleukin-2 receptor monoclonal antibody.
    Van Gelder T; Daane CR; Vaessen LM; Hesse CJ; Mochtar B; Balk AH; Weimar W
    Transpl Int; 1994; 7 Suppl 1():S556-8. PubMed ID: 11271306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of accelerated rejection of cardiac allografts in sensitized rats by anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy.
    Kupiec-Weglinski JW; Sablinski T; Hancock WW; Di Stefano R; Mariani G; Mix CT; Tilney NL
    Transplantation; 1991 Feb; 51(2):300-5. PubMed ID: 1825240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection.
    Baan CC; van Gelder T; Balk AH; Knoop CJ; Holweg CT; Maat LP; Weimar W
    Transplantation; 2000 Feb; 69(3):331-6. PubMed ID: 10706038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts.
    Tanaka K; Tilney NL; Stunkel KG; Hancock WW; Diamantstein T; Kupiec-Weglinski JW
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7375-9. PubMed ID: 2217171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful retreatment of allograft rejection with OKT3.
    First MR; Schroeder TJ; Hurtubise PE; Mansour ME; Penn I; Munda R; Balistreri WF; Alexander JW; Melvin DB; Fidler JP
    Transplantation; 1989 Jan; 47(1):88-91. PubMed ID: 2521410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation.
    Langrehr JM; Nüssler NC; Neumann U; Guckelberger O; Lohmann R; Radtke A; Jonas S; Klupp J; Steinmüller T; Lobeck H; Meuer S; Schlag H; Lemmens HP; Knoop M; Keck H; Bechstein WO; Neuhaus P
    Transplantation; 1997 Jun; 63(12):1772-81. PubMed ID: 9210503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.